Sitagliptin phosphate monohydrate, metformin hydrochloride

Key facts

Invented name
Velmetia
Active substance
Sitagliptin phosphate monohydrate, metformin hydrochloride
Therapeutic area
Endocrinology, -gynacology-fertility-metabolism
Decision number
P/116/2008
PIP number
Sitagliptin phosphate monohydrate, metformin hydrochloride
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Oral use
Contact for public enquiries
Merck Sharp and Dohme (Europe), Inc.
Belgium
E-mail: pip.information@merck.com
Tel. +31 412663179
Fax +31 412662571
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating